Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
|Videos|June 4, 2017
Dr. Soberman on the Next Generation of Multidisciplinary Care
Author(s)Mark S. Soberman, MD, MBA, FACS
Mark S. Soberman, MD, MBA, FACS, was elected as the 2017-2018 President of the Association of Community Cancer Centers (ACCC) discusses his vision for the next generation of multidisciplinary care in an interview during the 2017 ASCO Annual Meeting.
Advertisement
Mark S. Soberman, MD, MBA, FACS, the 2017 to 2018 President of the Association of Community Cancer Centers (ACCC), discusses his vision for the next-generation of multidisciplinary care in an interview during the 2017 ASCO Annual Meeting.
<<<
Advertisement
Related to this article
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
Five Under 5: Top Oncology Videos for the Week of 8/2
4
Revisit Every OncLive On Air Episode From July 2026
5